Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Pyxis Oncology, Inc. has received a consensus rating of "Moderate Buy" from five research firms, with an average 12-month price target of $8.67.
• The company reported a loss of ($0.30) earnings per share for the latest quarter, aligning this figure with an expected annual loss of ($1.04) per share.
• Institutional investors hold approximately 39.09% of Pyxis Oncology's stock, with notable increases in holdings from firms like Bank of America and Barclays.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.6667.

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Pyxis Oncology in a report on Tuesday, August 19th. Wall Street Zen raised shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 24th. Finally, Zacks Research raised shares of Pyxis Oncology from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.28 on Friday. The company has a market capitalization of $79.39 million, a P/E ratio of -0.80 and a beta of 1.13. The company's fifty day moving average is $1.18 and its two-hundred day moving average is $1.15. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.82 million during the quarter. As a group, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after buying an additional 9,062 shares in the last quarter. Barclays PLC boosted its holdings in Pyxis Oncology by 20.2% during the fourth quarter. Barclays PLC now owns 77,013 shares of the company's stock worth $121,000 after buying an additional 12,924 shares in the last quarter. ProShare Advisors LLC purchased a new stake in Pyxis Oncology during the fourth quarter worth about $26,000. Jane Street Group LLC boosted its holdings in Pyxis Oncology by 36.6% during the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock worth $106,000 after buying an additional 18,128 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Hedge funds and other institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.